Table 1.
Patient and tumor characteristics by pathological complete response (pCR) status
| Characteristic | No pCR | pCR |
|---|---|---|
| Patients (n = 146), n (%) | 90 (61.6) | 56 (38.4) |
| Age, mean ± SD, years | 54.9 ± 13.1 | 52.9 ± 12.6 |
| ER, n (%) | ||
| Negative (n = 55) | 22 (40) | 33 (60) |
| Positive (n = 91) | 68 (74.7) | 23 (25.3) |
| PR, n (%) | ||
| Negative (n = 85) | 39 (45.9) | 46 (54.1) |
| Positive (n = 61) | 51 (83.6) | 10 (16.4) |
| HER2, n (%) | ||
| Negative (n = 96) | 69 (71.9) | 27 (28.1) |
| Positive (n = 50) | 21 (42) | 29 (58) |
| cT, n (%) | ||
| cT1 (n = 56) | 34 (60.7) | 22 (39.3) |
| cT2–cT4 (n = 90) | 56 (62.2) | 34 (37.8) |
| Grading, n (%) | ||
| G1–G2 (n = 41) | 32 (78.1) | 9 (21.9) |
| G3 (n = 105) | 58 (55.3) | 47 (44.7) |
| LPBC, n (%) | ||
| 0–50% (n = 122) | 82 (67.2) | 40 (32.8) |
| 51–100% (n = 24) | 8 (33.3) | 16 (66.7) |
SD = Standard deviation; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; cT = clinical staging; LPBC = lymphocyte-predominant breast cancer.